Compare OPAL & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | CPIX |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 73.6M |
| IPO Year | 2021 | 2007 |
| Metric | OPAL | CPIX |
|---|---|---|
| Price | $2.38 | $2.80 |
| Analyst Decision | Sell | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.91 | N/A |
| AVG Volume (30 Days) | ★ 226.6K | 127.3K |
| Earning Date | 03-16-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 58.70 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $348,975,000.00 | $42,010,949.00 |
| Revenue This Year | $18.16 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | 16.34 | ★ 16.75 |
| 52 Week Low | $1.26 | $1.85 |
| 52 Week High | $4.08 | $6.27 |
| Indicator | OPAL | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 29.16 |
| Support Level | $2.09 | $2.78 |
| Resistance Level | $2.54 | $3.85 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 43.37 | 0.67 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.